RUNX1 anticorps

N° du produit ABIN2665355

Cet anticorps anti-RUNX1 Monoclonal Souris (Clone 1C5B16) (ABIN2665355) détecte spécifiquement RUNX1 dans FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour RUNX1 anticorps (ABIN2665355)

Antigène: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp RUNX1 est non-conjugé

Application: Flow Cytometry (FACS)

Clone: 1C5B16

Détail du produit anti-RUNX1 anticorps

Réactivité croisée: Souris, Humain

Réactivité croisée (Details): Human

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur RUNX1

Antigène: RUNX1 (Runt-Related Transcription Factor 1 (RUNX1))

Autre désignation: RUNX1

Sujet: RUNX1 belongs to the runt domain family of transcription factors and regulates target gene expression through forming a heterodimeric DNA-binding complex with CBFB. RUNX1 was first identified as a RUNX1-ETO fusion protein in acute myeloid leukaemia (AML) and is frequently mutated in AML and myelodysplastic syndrome due to chromosomal translocation. RUNX1-deficient mice fail to generate hematopoietic stem cells. RUNX1 regulates CD4 gene transcription during multiple stages of T cell development and represses the CD4 gene in CD4-CD8- (double negative) T cells. RUNX1 is also required for the differentiation of CD8+, Th17, and regulatory T cells. Impaired differentiation of megakaryocytes and decreased circulating platelet count was observed in the absence of RUNX1. These findings revealed that RUNX1 acts as a tumor suppressor for myeloid leukemia and is crucial for the development and terminal differentiation of several blood cell lineages.